A detailed history of State Street Corp transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, State Street Corp holds 3,469,068 shares of TSHA stock, worth $6.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,469,068
Previous 3,318,421 4.54%
Holding current value
$6.42 Million
Previous $7.43 Million 6.2%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.01 - $2.46 $302,800 - $370,591
150,647 Added 4.54%
3,469,068 $6.97 Million
Q2 2024

Aug 14, 2024

BUY
$2.04 - $4.17 $6.08 Million - $12.4 Million
2,978,901 Added 877.39%
3,318,421 $7.43 Million
Q1 2024

May 15, 2024

BUY
$1.43 - $3.25 $280,709 - $637,975
196,300 Added 137.06%
339,520 $974,000
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $4,256 - $9,216
3,200 Added 2.29%
143,220 $253,000
Q3 2023

Nov 14, 2023

BUY
$0.63 - $3.66 $15,813 - $91,866
25,100 Added 21.84%
140,020 $442,000
Q4 2022

Feb 14, 2023

BUY
$1.39 - $2.98 $52,124 - $111,750
37,500 Added 48.44%
114,920 $259,000
Q2 2022

Aug 15, 2022

SELL
$2.47 - $6.77 $1.04 Million - $2.86 Million
-421,794 Reduced 84.49%
77,420 $288,000
Q1 2022

May 16, 2022

BUY
$5.22 - $11.86 $182,934 - $415,633
35,045 Added 7.55%
499,214 $3.26 Million
Q4 2021

Feb 14, 2022

BUY
$11.43 - $19.2 $1.28 Million - $2.15 Million
111,983 Added 31.8%
464,169 $5.41 Million
Q3 2021

Nov 15, 2021

BUY
$15.82 - $21.57 $531,029 - $724,040
33,567 Added 10.54%
352,186 $6.56 Million
Q2 2021

Aug 16, 2021

BUY
$19.29 - $26.38 $3.79 Million - $5.18 Million
196,478 Added 160.86%
318,619 $6.76 Million
Q1 2021

May 17, 2021

BUY
$20.3 - $31.75 $244,310 - $382,111
12,035 Added 10.93%
122,141 $2.48 Million
Q4 2020

Feb 16, 2021

BUY
$19.14 - $28.13 $2.11 Million - $3.1 Million
110,106 New
110,106 $2.92 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $89.5M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.